See more : SBI Cards and Payment Services Limited (SBICARD.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Trillium Therapeutics Inc. (TRIL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Trillium Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sumitomo Corporation (SSUMF) Income Statement Analysis – Financial Results
- Organización Cultiba, S.A.B. de C.V. (CULTIBAB.MX) Income Statement Analysis – Financial Results
- Kura Sushi,Inc. (2695.T) Income Statement Analysis – Financial Results
- The Great Taipei Gas Corporation (9908.TW) Income Statement Analysis – Financial Results
- Menon Bearings Limited (MENONBE.NS) Income Statement Analysis – Financial Results
Trillium Therapeutics Inc. (TRIL)
About Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 148.00K | 124.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 147.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 148.00 | 124.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.10% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 25.35M | 25.30M | 31.88M | 29.53M | 22.16M | 13.01M | 9.13M | 3.13M | 626.79K | 818.29K | 1.76M | 2.26M | 2.22M | 1.87M | 1.85M | 888.00K | 171.39K |
| General & Administrative | 36.26M | 4.31M | 2.63M | 3.07M | 2.93M | 2.29M | 2.22M | 903.67K | 468.71K | 1.41M | 2.44M | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.26M | 4.31M | 2.63M | 3.07M | 2.93M | 2.29M | 2.22M | 903.67K | 468.71K | 1.41M | 2.44M | 1.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 3.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 902.08K | 269.33K | 287.57K | 2.41M | 3.52M | -6.01M | 1.78M | 559.18K |
| Operating Expenses | 61.60M | 32.61M | 34.51M | 32.60M | 25.09M | 15.30M | 11.35M | 4.04M | 1.10M | 3.13M | 4.47M | 4.47M | 4.63M | 5.38M | -4.16M | 2.67M | 730.58K |
| Cost & Expenses | 61.60M | 35.56M | 34.51M | 32.60M | 25.09M | 15.30M | 11.35M | 4.04M | 1.10M | 3.13M | 4.47M | 4.47M | 4.63M | 5.38M | -4.16M | 2.67M | 730.58K |
| Interest Income | 2.01M | 614.00K | 795.87K | 574.16K | 310.63K | 352.01K | 326.22K | 41.43K | 25.87K | 35.66K | 8.06K | 18.85K | 191.64K | 0.00 | 85.68K | 136.08K | 0.00 |
| Interest Expense | 0.00 | 177.00K | 31.57K | 54.08K | 48.63K | 52.89K | 60.10K | 37.69K | 0.00 | 14.03K | 0.00 | 0.00 | 133.84K | 0.00 | 284.56K | 307.87K | 0.00 |
| Depreciation & Amortization | 591.00K | 2.11M | 2.31M | 3.74M | 3.19M | 329.86K | 566.81K | 609.32K | 6.42K | 250.35K | 258.05K | 257.54K | 227.09K | 285.51K | 246.01K | 235.71K | 53.07K |
| EBITDA | -58.65M | -39.31M | -28.85M | -32.05M | -23.11M | -10.23M | -10.47M | -3.38M | -1.06M | -2.84M | -4.20M | -4.19M | -4.21M | -5.22M | -3.55M | -2.27M | -737.08K |
| EBITDA Ratio | -39,630.41% | -31,702.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -61.46M | -35.44M | -34.51M | -32.60M | -25.09M | -15.30M | -11.35M | -4.04M | -1.10M | -3.13M | -4.47M | -4.47M | -4.63M | -5.38M | 4.16M | -2.67M | -730.58K |
| Operating Income Ratio | -41,523.65% | -28,579.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.21M | -6.16M | 3.33M | -3.25M | -1.26M | 4.69M | 251.06K | 9.01K | 28.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -59.24M | -41.59M | -31.19M | -35.85M | -26.35M | -10.61M | -11.10M | -4.03M | -1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -40,029.73% | -33,543.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 102.00K | 28.00K | 5.87K | 3.18K | -2.74M | 6.85K | 311.16K | 46.71K | 28.48K | 14.03K | 0.00 | 0.00 | 133.84K | 0.00 | 284.56K | 307.87K | 0.00 |
| Net Income | -59.35M | -41.62M | -31.19M | -35.86M | -23.61M | -10.62M | -11.10M | -4.03M | -1.07M | -3.11M | -4.46M | -4.45M | -4.57M | -5.51M | -4.08M | -2.82M | -790.15K |
| Net Income Ratio | -40,098.65% | -33,566.13% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.71 | -1.65 | -2.24 | -3.67 | -3.02 | -1.60 | -2.64 | -2.97 | -17.15 | -5.11 | -8.53 | -9.76 | -12.41 | -23.10 | -23.16 | -15.50 | -0.01 |
| EPS Diluted | -0.71 | -1.65 | -2.24 | -3.67 | -3.02 | -1.60 | -2.64 | -2.97 | -17.15 | -5.11 | -8.53 | -9.76 | -12.41 | -23.10 | -20.36 | -14.13 | -0.01 |
| Weighted Avg Shares Out | 83.75M | 25.26M | 13.91M | 9.77M | 7.82M | 6.64M | 4.20M | 1.36M | 62.21K | 608.26K | 522.68K | 455.62K | 368.01K | 238.38K | 176.29K | 181.67K | 105.00M |
| Weighted Avg Shares Out (Dil) | 83.75M | 25.26M | 13.91M | 9.77M | 7.82M | 6.64M | 4.20M | 1.36M | 62.21K | 608.26K | 522.68K | 455.62K | 368.01K | 238.38K | 200.54K | 199.29K | 105.00M |
Did You Miss Out on a 5000% Gain With Trillium Stock?
A new CEO and prioritization of research could have more big gains in store for the company
Trillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021
CAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ( “ Trillium ” or the “ Company ” ) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, recently presented at the...
These Were the 5 Best Cancer Stocks Of 2020
Biotech investors had more than just vaccines to think about this year.
This Biotech Is Up 1,500% This Year. Can It Make You Rich in 2021?
Investors are catching on to the opportunity for this innovative cancer therapy, and so is big pharma.
Trillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the presentation of clinical data at the upcoming American Society of Hematology...
Trillium Therapeutics Reports Third Quarter 2020 Financial and Operating Results
CAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the nine months...
Trillium Therapeutics: Investors To See Further Upside Via CD47 Focus
Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadth of haematologic cancers as CD47 targeting drugs.
Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board Industry Veteran Brings Deep Executive and Commercial Experience to Trillium Board
2 Cancer Stocks That Could Make You Filthy Rich
Adaptimmune Therapeutics and Trillium Therapeutics could be big winners for early shareholders.
Trillium Therapeutics Announces Formation of Scientific Advisory Board
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the formation of a Scientific Advisory Board (“SAB”),...
Source: https://incomestatements.info
Category: Stock Reports